RYZ101 + carboplatin + etoposide + atezolizumab

**RYZ101 + carboplatin + etoposide + atezolizumab** is an investigational multi-agent regimen combining a targeted radiopharmaceutical, two chemotherapeutic agents, and an immune checkpoint inhibitor. - **RYZ101 (225Ac-DOTATATE)** is a first-in-class, highly potent alpha-emitting radiopharmaceutical that targets somatostatin receptor-positive (SSTR+) tumors, notably in well-differentiated neuroendocrine tumors (NETs). It utilizes actinium-225 conjugated to DOTATATE, causing lethal double-strand DNA breaks via short-range, high-energy alpha-particle emission[1][3][5][7][9]. - **Carboplatin** is a platinum-based small molecule chemotherapy drug that crosslinks DNA, inhibiting DNA replication and transcription, leading to apoptosis[2][4][6][8]. - **Etoposide** is a topoisomerase II inhibitor chemotherapy that causes DNA breaks and apoptosis in rapidly dividing cells[2][4][6][8]. - **Atezolizumab** is a monoclonal antibody and immune checkpoint inhibitor targeting programmed cell death-ligand 1 (PD-L1), blocking immune escape and activating T-cell mediated anti-tumor immunity. This regimen is likely investigational, intended for advanced neuroendocrine tumors and may be explored for other SSTR+ solid tumors or refractory cancers; approved indications for the full combination are not established, but individual components have clinical precedence in cancer care[1][3][4][6][9].

Other names

actinium Ac 225 DOTATATE + carboplatin + etoposide + atezolizumab